Posaconazole: Difference between revisions
From IDWiki
(Created page with "== Therapeutic Drug Monitoring == * Measure trough 7 days after starting or adjusting dose, or adjusting interacting medications, or concerns of poor adherence or absorption *...") |
No edit summary |
||
(4 intermediate revisions by the same user not shown) | |||
Line 1: | Line 1: | ||
− | == |
+ | ==Therapeutic Drug Monitoring== |
− | * Measure trough 7 days after starting or adjusting dose, or adjusting interacting medications, or concerns of poor adherence or absorption |
||
− | * For prophylaxis, target trough >0.7 mg/L, or random level 0.35 mg/L 48 h after starting therapy |
||
− | * For treatment, target trough >1 mg/L |
||
+ | *Measure trough 7 days after starting or adjusting dose, or adjusting interacting medications, or concerns of poor adherence or absorption |
||
− | [[Category:Antifungals]] |
||
+ | *For prophylaxis, target trough >0.7 mg/L, or random level 0.35 mg/L 48 h after starting therapy |
||
+ | *For treatment, target trough >1 mg/L |
||
+ | |||
+ | ===Clinical Breakpoints=== |
||
+ | {| class="wikitable" |
||
+ | ! rowspan="2" |Species |
||
+ | ! rowspan="2" |ECV (μg/mL) |
||
+ | ! colspan="4" |Breakpoints (μg/mL) |
||
+ | ! colspan="4" |Breakpoints (mm) |
||
+ | |- |
||
+ | !S |
||
+ | !SDD |
||
+ | !I |
||
+ | !R |
||
+ | !S |
||
+ | !SDD |
||
+ | !I |
||
+ | !R |
||
+ | |- |
||
+ | |[[Candida albicans]] |
||
+ | |0.06 |
||
+ | |≤0.06 |
||
+ | | |
||
+ | | |
||
+ | |≥0.12 |
||
+ | | |
||
+ | | |
||
+ | | |
||
+ | | |
||
+ | |- |
||
+ | |[[Candida dubliniensis]] |
||
+ | | |
||
+ | | |
||
+ | | |
||
+ | | |
||
+ | | |
||
+ | | |
||
+ | | |
||
+ | | |
||
+ | | |
||
+ | |- |
||
+ | |[[Candida glabrata]] |
||
+ | |2 |
||
+ | | |
||
+ | | |
||
+ | | |
||
+ | | |
||
+ | | |
||
+ | | |
||
+ | | |
||
+ | | |
||
+ | |- |
||
+ | |[[Candida guilliermondii]] |
||
+ | |0.5 |
||
+ | | |
||
+ | | |
||
+ | | |
||
+ | | |
||
+ | | |
||
+ | | |
||
+ | | |
||
+ | | |
||
+ | |- |
||
+ | |[[Candida kefyr]] |
||
+ | |0.25 |
||
+ | | |
||
+ | | |
||
+ | | |
||
+ | | |
||
+ | | |
||
+ | | |
||
+ | | |
||
+ | | |
||
+ | |- |
||
+ | |[[Candida krusei]] |
||
+ | |0.5 |
||
+ | | |
||
+ | | |
||
+ | | |
||
+ | | |
||
+ | | |
||
+ | | |
||
+ | | |
||
+ | | |
||
+ | |- |
||
+ | |[[Candida lusitaniae]] |
||
+ | |0.12 |
||
+ | | |
||
+ | | |
||
+ | | |
||
+ | | |
||
+ | | |
||
+ | | |
||
+ | | |
||
+ | | |
||
+ | |- |
||
+ | |[[Candida parapsilosis]] |
||
+ | |0.25 |
||
+ | |≤0.06 |
||
+ | | |
||
+ | | |
||
+ | |≥0.12 |
||
+ | | |
||
+ | | |
||
+ | | |
||
+ | | |
||
+ | |- |
||
+ | |[[Candida tropicalis]] |
||
+ | |0.12 |
||
+ | |≤0.06 |
||
+ | | |
||
+ | | |
||
+ | |≥0.12 |
||
+ | | |
||
+ | | |
||
+ | | |
||
+ | | |
||
+ | |- |
||
+ | |[[Cryptococcus neoformans]] |
||
+ | | |
||
+ | | colspan="8" rowspan="2" | |
||
+ | |- |
||
+ | |[[Cryptococcus gattii]] |
||
+ | | |
||
+ | |} |
||
+ | |||
+ | == Safety == |
||
+ | |||
+ | === Adverse Events === |
||
+ | |||
+ | * Liver toxicity |
||
+ | ** Generally transient and asymptomatic and self-limited |
||
+ | ** See also [https://www.ncbi.nlm.nih.gov/books/NBK548934/ LiverTox] |
||
+ | |||
+ | [[Category:Triazoles]] |
Latest revision as of 09:24, 30 March 2022
Therapeutic Drug Monitoring
- Measure trough 7 days after starting or adjusting dose, or adjusting interacting medications, or concerns of poor adherence or absorption
- For prophylaxis, target trough >0.7 mg/L, or random level 0.35 mg/L 48 h after starting therapy
- For treatment, target trough >1 mg/L
Clinical Breakpoints
Species | ECV (μg/mL) | Breakpoints (μg/mL) | Breakpoints (mm) | ||||||
---|---|---|---|---|---|---|---|---|---|
S | SDD | I | R | S | SDD | I | R | ||
Candida albicans | 0.06 | ≤0.06 | ≥0.12 | ||||||
Candida dubliniensis | |||||||||
Candida glabrata | 2 | ||||||||
Candida guilliermondii | 0.5 | ||||||||
Candida kefyr | 0.25 | ||||||||
Candida krusei | 0.5 | ||||||||
Candida lusitaniae | 0.12 | ||||||||
Candida parapsilosis | 0.25 | ≤0.06 | ≥0.12 | ||||||
Candida tropicalis | 0.12 | ≤0.06 | ≥0.12 | ||||||
Cryptococcus neoformans | |||||||||
Cryptococcus gattii |
Safety
Adverse Events
- Liver toxicity
- Generally transient and asymptomatic and self-limited
- See also LiverTox